Emergent BioSolutions Inc. (EBS)
USD 8.16
(-7.17%)
USD 8.16
(-7.17%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 877.5 Million USD | -37.58% |
| 2022 | 1.4 Billion USD | 67.16% |
| 2021 | 841 Million USD | -3.86% |
| 2020 | 874.8 Million USD | 7.83% |
| 2019 | 811.3 Million USD | 2.1% |
| 2018 | 794.6 Million USD | 5804.73% |
| 2017 | 13.45 Million USD | -94.98% |
| 2016 | 268.09 Million USD | 5.97% |
| 2015 | 253 Million USD | 0.8% |
| 2014 | 251 Million USD | 304.84% |
| 2013 | 62 Million USD | -1.23% |
| 2012 | 62.77 Million USD | 5.58% |
| 2011 | 59.45 Million USD | 25.36% |
| 2010 | 47.42 Million USD | -27.83% |
| 2009 | 65.71 Million USD | 14.93% |
| 2008 | 57.18 Million USD | -1.3% |
| 2007 | 57.93 Million USD | 35.45% |
| 2006 | 42.77 Million USD | 259.12% |
| 2005 | 11.91 Million USD | -7.44% |
| 2004 | 12.86 Million USD | 0.0% |
| 2002 | - USD | -100.0% |
| 2001 | 33.8 Million USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 876.8 Million USD | -4.92% |
| 2024 Q1 | 922.2 Million USD | 5.09% |
| 2023 Q1 | 1.39 Billion USD | -0.53% |
| 2023 Q3 | 413.6 Million USD | -54.21% |
| 2023 Q2 | 903.2 Million USD | -35.41% |
| 2023 FY | 877.5 Million USD | -37.58% |
| 2023 Q4 | 877.5 Million USD | 112.16% |
| 2022 FY | 1.4 Billion USD | 67.16% |
| 2022 Q2 | 825.2 Million USD | -0.95% |
| 2022 Q1 | 833.1 Million USD | -0.94% |
| 2022 Q3 | 1.05 Billion USD | 27.64% |
| 2022 Q4 | 1.4 Billion USD | 33.47% |
| 2021 Q2 | 854 Million USD | -0.59% |
| 2021 Q1 | 859.1 Million USD | -1.79% |
| 2021 Q4 | 841 Million USD | -0.93% |
| 2021 Q3 | 848.9 Million USD | -0.6% |
| 2021 FY | 841 Million USD | -3.86% |
| 2020 Q4 | 874.8 Million USD | -0.52% |
| 2020 FY | 874.8 Million USD | 7.83% |
| 2020 Q1 | 789.2 Million USD | -2.72% |
| 2020 Q2 | 787.2 Million USD | -0.25% |
| 2020 Q3 | 879.4 Million USD | 11.71% |
| 2019 Q2 | 840.5 Million USD | 13.2% |
| 2019 Q1 | 742.5 Million USD | -6.56% |
| 2019 FY | 811.3 Million USD | 2.1% |
| 2019 Q3 | 823.4 Million USD | -2.03% |
| 2019 Q4 | 811.3 Million USD | -1.47% |
| 2018 FY | 794.6 Million USD | 5804.73% |
| 2018 Q1 | 13.46 Million USD | 0.09% |
| 2018 Q2 | 13.48 Million USD | 0.1% |
| 2018 Q4 | 794.6 Million USD | 5788.11% |
| 2018 Q3 | 13.49 Million USD | 0.1% |
| 2017 Q4 | 13.45 Million USD | -94.6% |
| 2017 Q2 | 248.69 Million USD | 0.12% |
| 2017 FY | 13.45 Million USD | -94.98% |
| 2017 Q1 | 248.39 Million USD | -7.35% |
| 2017 Q3 | 248.99 Million USD | 0.12% |
| 2016 Q3 | 267.79 Million USD | 8.25% |
| 2016 FY | 268.09 Million USD | 5.97% |
| 2016 Q4 | 268.09 Million USD | 0.11% |
| 2016 Q2 | 247.39 Million USD | 0.08% |
| 2016 Q1 | 247.19 Million USD | -2.3% |
| 2015 Q4 | 253 Million USD | 0.0% |
| 2015 Q2 | 253 Million USD | 0.8% |
| 2015 Q1 | 251 Million USD | 0.0% |
| 2015 FY | 253 Million USD | 0.8% |
| 2015 Q3 | 253 Million USD | 0.0% |
| 2014 Q2 | 251 Million USD | 0.0% |
| 2014 FY | 251 Million USD | 304.84% |
| 2014 Q3 | 251 Million USD | 0.0% |
| 2014 Q1 | 251 Million USD | 304.84% |
| 2014 Q4 | 251 Million USD | 0.0% |
| 2013 Q1 | 61.65 Million USD | -1.78% |
| 2013 Q3 | 59.42 Million USD | -1.85% |
| 2013 Q2 | 60.53 Million USD | -1.81% |
| 2013 Q4 | 62 Million USD | 4.34% |
| 2013 FY | 62 Million USD | -1.23% |
| 2012 FY | 62.77 Million USD | 5.58% |
| 2012 Q2 | 62.19 Million USD | 2.18% |
| 2012 Q3 | 63.01 Million USD | 1.31% |
| 2012 Q4 | 62.77 Million USD | -0.38% |
| 2012 Q1 | 60.87 Million USD | 2.39% |
| 2011 Q2 | 39.3 Million USD | -15.63% |
| 2011 FY | 59.45 Million USD | 25.36% |
| 2011 Q1 | 46.58 Million USD | -1.78% |
| 2011 Q3 | 53.79 Million USD | 36.87% |
| 2011 Q4 | 59.45 Million USD | 10.52% |
| 2010 FY | 47.42 Million USD | -27.83% |
| 2010 Q2 | 49.09 Million USD | -24.42% |
| 2010 Q1 | 64.96 Million USD | -1.15% |
| 2010 Q4 | 47.42 Million USD | -1.73% |
| 2010 Q3 | 48.26 Million USD | -1.7% |
| 2009 Q1 | 56.52 Million USD | -1.15% |
| 2009 Q4 | 65.71 Million USD | 66.01% |
| 2009 FY | 65.71 Million USD | 14.93% |
| 2009 Q3 | 39.58 Million USD | -28.75% |
| 2009 Q2 | 55.55 Million USD | -1.71% |
| 2008 Q3 | 58.39 Million USD | -1.55% |
| 2008 Q2 | 59.31 Million USD | -1.52% |
| 2008 Q1 | 60.22 Million USD | 3.96% |
| 2008 FY | 57.18 Million USD | -1.3% |
| 2008 Q4 | 57.18 Million USD | -2.07% |
| 2007 Q4 | 57.93 Million USD | 23.33% |
| 2007 FY | 57.93 Million USD | 35.45% |
| 2007 Q2 | 32.61 Million USD | -2.3% |
| 2007 Q1 | 33.38 Million USD | -21.95% |
| 2007 Q3 | 46.97 Million USD | 44.01% |
| 2006 FY | 42.77 Million USD | 259.12% |
| 2006 Q4 | 42.77 Million USD | 17.27% |
| 2006 Q3 | 36.47 Million USD | 0.0% |
| 2005 Q4 | 11.91 Million USD | 0.0% |
| 2005 FY | 11.91 Million USD | -7.44% |
| 2004 FY | 12.86 Million USD | 0.0% |
| 2004 Q4 | 12.86 Million USD | 0.0% |
| 2002 FY | - USD | -100.0% |
| 2001 Q4 | 31.6 Million USD | 0.0% |
| 2001 FY | 33.8 Million USD | 0.0% |
| 2000 Q4 | 957.3 Million USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Amneal Pharmaceuticals, Inc. | 2.75 Billion USD | 68.097% |
| Bausch Health Companies Inc. | 22.38 Billion USD | 96.08% |
| Catalent, Inc. | 4.98 Billion USD | 82.408% |
| Elanco Animal Health Incorporated | 5.77 Billion USD | 84.803% |
| Perrigo Company plc | 4.07 Billion USD | 78.458% |
| Teva Pharmaceutical Industries Limited | 20.15 Billion USD | 95.646% |
| Zoetis Inc. | 6.8 Billion USD | 87.101% |